Maiken Cavling Arendrup1,2, Paul E Verweij3,4, Johan W Mouton5, Katrien Lagrou6,7, Joseph Meletiadis5,8. 1. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark. 2. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 3. Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, The Netherlands. 4. Centre of Expertise in Mycology, Radboudumc/CWZ, Nijmegen, The Netherlands. 5. Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands. 6. National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium. 7. Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium. 8. Clinical Microbiology Laboratory, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
OBJECTIVES: Azole-resistant Aspergillus fumigatus is emerging worldwide. Reference susceptibility testing methods are technically demanding and no validated commercial susceptibility tests for moulds currently exist. In this multicentre study a 4-well azole-containing screening agar method was evaluated using clinically relevant isolates. METHODS: Forty WT and 39 cyp51A mutant A. fumigatus [G54 (n = 10), M220 (n = 10), TR34/L98H (n = 9) and TR46/Y121F/T289A (n = 10)] were tested individually and as simulated mixed samples (sampling 4 WT and 1 mutant colonies). EUCAST MICs were determined following E.Def 9.3. In-house and commercial 4-well plates containing agars supplemented with 4 mg/L itraconazole, 1 mg/L voriconazole, 0.5 mg/L posaconazole and no antifungal, respectively, were evaluated. Growth was scored (0-3) by two independent observers in three laboratories. Inter-plate, inter-observer, essential and categorical agreement, sensitivity and specificity were calculated. RESULTS: CYP51A genotype and antifungal compound-specific MICs and growth patterns were documented. The inter-observer agreement was excellent with 86%-99% identical scores (range 80%-100%) for both plates. The qualitative agreement (no growth versus growth) was excellent (median 95%-100%, range 87%-100%, overall). The overall sensitivity and specificity for the 4-well plate (no growth versus growth) was 99% (range 97%-100%) and 99% (95%-100%), respectively. The sensitivity for simulated WT/mutant specimens was 94% (range 83%-100%) for the WT-TR34/L98H combination, but 100% for the WT/G54W combination. The performance remained unchanged using only itraconazole- and voriconazole-containing agars, but was lower for the other combinations. CONCLUSIONS: Implementation of the 4-well screening plate in routine laboratories will allow easy and reliable detection of the most common azole-resistant A. fumigatus.
OBJECTIVES: Azole-resistant Aspergillus fumigatus is emerging worldwide. Reference susceptibility testing methods are technically demanding and no validated commercial susceptibility tests for moulds currently exist. In this multicentre study a 4-well azole-containing screening agar method was evaluated using clinically relevant isolates. METHODS: Forty WT and 39 cyp51A mutant A. fumigatus [G54 (n = 10), M220 (n = 10), TR34/L98H (n = 9) and TR46/Y121F/T289A (n = 10)] were tested individually and as simulated mixed samples (sampling 4 WT and 1 mutant colonies). EUCAST MICs were determined following E.Def 9.3. In-house and commercial 4-well plates containing agars supplemented with 4 mg/L itraconazole, 1 mg/L voriconazole, 0.5 mg/L posaconazole and no antifungal, respectively, were evaluated. Growth was scored (0-3) by two independent observers in three laboratories. Inter-plate, inter-observer, essential and categorical agreement, sensitivity and specificity were calculated. RESULTS: CYP51A genotype and antifungal compound-specific MICs and growth patterns were documented. The inter-observer agreement was excellent with 86%-99% identical scores (range 80%-100%) for both plates. The qualitative agreement (no growth versus growth) was excellent (median 95%-100%, range 87%-100%, overall). The overall sensitivity and specificity for the 4-well plate (no growth versus growth) was 99% (range 97%-100%) and 99% (95%-100%), respectively. The sensitivity for simulated WT/mutant specimens was 94% (range 83%-100%) for the WT-TR34/L98H combination, but 100% for the WT/G54W combination. The performance remained unchanged using only itraconazole- and voriconazole-containing agars, but was lower for the other combinations. CONCLUSIONS: Implementation of the 4-well screening plate in routine laboratories will allow easy and reliable detection of the most common azole-resistant A. fumigatus.
Authors: Joseph Meletiadis; Maria Siopi; Lamprini Kanioura; Karin Meinike Jørgensen; David S Perlin; Johan W Mouton; Maiken Cavling Arendrup Journal: J Antimicrob Chemother Date: 2019-08-01 Impact factor: 5.790
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: Jochem B Buil; Eveline Snelders; Laura Bedin Denardi; Willem J G Melchers; Paul E Verweij Journal: Emerg Infect Dis Date: 2019-01 Impact factor: 6.883
Authors: Carla Viegas; Gerard T A Fleming; Abdul Kadir; Beatriz Almeida; Liliana Aranha Caetano; Anita Quintal Gomes; Magdalena Twarużek; Robert Kosicki; Susana Viegas; Ann Marie Coggins Journal: Microorganisms Date: 2020-01-15
Authors: Pieter P A Lestrade; Jochem B Buil; Martha T van der Beek; Ed J Kuijper; Karin van Dijk; Greetje A Kampinga; Bart J A Rijnders; Alieke G Vonk; Sabine C de Greeff; Annelot F Schoffelen; Jaap van Dissel; Jacques F Meis; Willem J G Melchers; Paul E Verweij Journal: Emerg Infect Dis Date: 2020-07 Impact factor: 6.883